跳至主要内容
临床试验/IRCT20200324046847N1
IRCT20200324046847N1招募中2 期

Study the Efficacy and Safety of SeptimebTM in the Treatment of COVID-19 Infection in Iranian Patients: A Clinical Trial (Case Series)

Tehran University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • •Age between 18-65 years
  • •Known case of Covid-19 by relative signs, symptoms, Lab. radiology and CT scan Data
  • •Existence of Severe symptoms and signs of the disease (infection by COVID-19)
  • •Not taking any immunstimulators during last three months.
  • •Completed consent form by the patients or guardians

排除标准

  • •Recent drug abuse or alcohol consumption. Taking growth hormone, testosterone or anabolic steroids during last 30 days.Long term use of immunosuppressives. Chemotherapy, treatment by interferon or radiotherapy during last 3 weeks•
  • •Pregnancy or breast feeding
  • •Positive symptoms for common cold or positive PCR result for influenza but not confirmed COVID-19

研究者

相似试验